Law360 (September 4, 2019, 5:32 PM EDT) — A California federal judge has partly granted Lannett’s bid to dismiss a suit accusing it of misleading consumers into believing that its cocaine-based anesthetic, on the market since at least 2008, had received government approval, but he also allowed false advertising claims against the company to continue.
U.S. District Judge William Orrick on Tuesday dismissed Genus Lifesciences Inc.’s claims that Lannett Co. Inc.’s advertising of the drug C-Topical harmed competition, but he did not dismiss claims that the packaging and labeling of C-Topical misled consumers into thinking that the U.S. Food and Drug Administration had approved the drug.
“I am unpersuaded…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!